EU approves CSL Behring's Privigen for CIDP

04/8/2013 | Pharmaceutical Business Review Online

The European Commission granted CSL Behring approval to market Privigen, an intravenous immune globulin, as a treatment for chronic inflammatory demyelinating polyneuropathy. Positive results from the Privigen Impact on Mobility and Autonomy trial were cited in the application.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ